Cooper Companies Director Rosebrough Buys 10,000 Shares for $542,000. What Does His Move Say About This Eye Care Stock?

Walter M. Jr Rosebrough, a Director at The Cooper Companies, Inc. (NASDAQ:COO), purchased 10,000 shares of common stock in transactions executed on Sept. 11, 2026 and Sept. 14, 2026, as disclosed in a recent SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average purchase price ($54.16); post-transaction value based on Sept. 14, 2026 market close ($54.22).

Key questions

• What is the distribution of the insider's current equity holdings?
  The vast majority of the director's position is held indirectly through the Walter M Rosebrough, Jr Revocable Trust. Following the latest purchase, this entity holds 20,000 shares, while the director retains 832 shares in direct ownership.
• How does the execution price compare to the current market valuation?
  The shares were purchased at a weighted average price of $54.16. This level sits slightly above the Sept. 15, 2026 market close of $53.27 but below the $54.22 close recorded on the final day of the transaction period.
• What was the scale of this acquisition relative to the insider's existing stake?
  This purchase of 10,000 shares represents a substantial shift in the insider's position, as the volume of shares acquired was equal to 92% of the total shares held before the filing.
• What is the broader context of the insider's total beneficial ownership?
  With the addition of these 10,000 shares, the insider's total beneficial ownership in the company is 20,832 shares. This results in an estimated ownership percentage of slightly more than 0.01% of the company's outstanding common stock.

Company Overview

Company Snapshot

• The Cooper Companies develops, manufactures, and distributes a comprehensive portfolio of vision care and surgical products through two primary business units: CooperVision, which specializes in contact lenses, including spherical, toric, multifocal, and myopia management solutions, and CooperSurgical, which provides surgical instruments and supplies for ophthalmic and women's health procedures.
• The company generates revenue through the sale of contact lens products, surgical instruments, and related healthcare supplies to eye care professionals, surgical centers, and healthcare providers globally, leveraging a diversified product portfolio across multiple therapeutic categories and geographic markets.
• The Cooper Companies serves eye care practitioners, ophthalmologists, surgical centers, and healthcare institutions worldwide, with particular focus on patients requiring vision correction solutions and healthcare providers performing ophthalmic and women's health surgical procedures.

The Cooper Companies is a global medical device manufacturer with approximately 15,000 employees and a market capitalization of $10.4 billion, generating $4.2 billion in trailing twelve-month (TTM) revenue. The company maintains a competitive position in the vision care and surgical markets through its dual-business-unit structure, offering both consumer-facing contact lens products and professional-grade surgical instruments that address substantial global demand for vision correction and surgical solutions.

What this transaction means for investors

Rosebrough currently serves as CEO Emeritus and Senior Advisor of Steris plc (NYSE:STE), a global medical device business focused on infection prevention products and services. He only joined the board of Cooper Companies at the start of 2026, but his track record at Steris suggests he knows the healthcare business inside and out. It is bullish that he's buying.

There are many reasons an insider may sell a company's shares. One reason could be the need to raise cash to fund a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company's future.

However, there is only one reason an insider buys stock: they believe the share price is going up.

By that investor's rule of thumb, Rosebrough's purchase of Cooper Companies' shares is inherently bullish.

On top of that, studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.

Cooper was considering spinning off or selling its surgical unit, but opted to keep it in-house. That's a sign that they believe there is more value to owning the business ahead. For the current fourth quarter of its fiscal year, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. That's not great, but management believes it sets the stage for a better 2027.

Insider buying, like Rosebrough's, suggests a belief in the company's long-term growth and profitability for shareholders.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.